BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’

Boston Scientific (BSX) lowered its full-year adjusted earnings outlook to $3.16-$3.18 per share and expects Q4 sales to decline 1-3%. Q3 sales rose 1.5% to $5.14B, beating estimates. The company cited a cybersecurity attack for disruptions. Shares fell 8%, hitting 4-year lows. CEO remains confident in long-term strategy.

Original reporting
Published Oct 28, 2026, 2:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 2:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’ — source image
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance cut is the primary catalyst for the stock move; the cyber incident adds a risk overlay.

02

Market read

First‑time disclosure of lower earnings guidance and Q4 sales decline for a large‑cap med‑tech firm, driving immediate price action.

03

What to watch

CEO's confidence in long‑term strategy and pipeline of new technologies could support a rebound once the disruption clears.

Relevance 9/10Novelty 9/10Timing: today

Background

Boston Scientific disclosed a cyber‑attack that disrupted manufacturing and order processing, which may have contributed to the weaker outlook.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific lowered its full-year adjusted earnings outlook to $3.16‑$3.18 per share and warned Q4 sales will decline 1‑3%, triggering an 8% share drop.

Expected impact

likely further pressure as investors price in weaker outlook

Evidence & confidence

The new guidance is materially below prior expectations and was announced alongside an 8% intraday sell‑off, indicating fresh negative sentiment.

Market effects

Medical device sector may see broader pressure as the outlook hints at demand softness.

U.S. healthcare stocks could face short‑term weakness.

Limited to investors with exposure to Boston Scientific and related med‑tech peers.

Counterpoint

If the cybersecurity incident is resolved quickly, the sales dip may be temporary, offering a buying opportunity at lower levels.

Key entities

  • Mike Mahoney

    CEO of Boston Scientific, reaffirmed confidence in long‑term strategy.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.